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Melanocortin receptors are critical modulators of energy balance and glucose homeostasis. Companion
studies published in Science (Asai et al., 2013; Sebag et al., 2013) establish a role for melanocortin receptor
accessory protein 2 (Mrap2) in regulating melanocortin receptor activity and in the development of obesity in
zebrafish, rodents, and humans.The rates of obesity and diabetes are ris-
ing around the world. Although environ-
mental conditions have been implicated
in these diseases, accumulating evidence
suggests genetics also contributes to
early-onset and severe obesity. Themela-
nocortin system provides one example
(Balthasar et al., 2005; Cone, 2006;
Greenfield et al., 2009; Sohn et al.,
2013). It is comprised of ligands and a
family of receptors (MC1–5 receptors)
that directly link to a myriad of bio-
physiological systems regulating food
intake, energy expenditure, body length,
and glucose metabolism (Cone, 2006).
Notably, disruptions of MC4 receptors in
rodents result in severe obesity and dia-
betes (Cone, 2006). Moreover, mutations
of MC4 receptors in humans lead to
analogous deficits of metabolism and
are the most common monogenic form
of human obesity (Cone, 2006; Greenfield
et al., 2009). Thus, understanding the
molecular mechanisms responsible for
regulating MC4 signaling may lead tobetter therapies targeting body weight
and glucose homeostasis. Now, com-
panion articles (Asai et al., 2013; Sebag
et al., 2013) in the journal Science add
a new layer of complexity to the regula-
tion of MC4 receptors. They report that
melanocortin receptor accessory protein
2 (Mrap2) coordinates signaling by MC4
receptors and demonstrate that Mrap2
is required for growth and development,
as well as metabolism, across species
including humans (Asai et al., 2013;
Sebag et al., 2013).
MC4 receptors are G protein-coupled
receptors (GPCRs) that stimulate
classical signaling cascades, which ulti-
mately regulate metabolism at least in
part via expression in sites involved in
autonomic and endocrine function,
including the paraventricular nucleus of
the hypothalamus (PVH) (Balthasar
et al., 2005; Cone, 2006). However,
recent work suggests that melanocortin
signaling is more complicated than pre-
viously anticipated. In particular, mela-nocortin receptor accessory proteins
(Mrap1 and Mrap2) regulate transport
of melanocortin receptors to the cell
membrane and also abrogate or facili-
tate ligand-induced activation of intracel-
lular signaling (Ramachandrappa et al.,
2013). Asai et al. now demonstrate that
Mrap2 is highly expressed in the PVH,
including cells expressing the MC4 re-
ceptor (Asai et al., 2013; Cone, 2006).
In agreement with Mrap2 playing a role
in MC4 receptor signaling (Figure 1),
they also find that rodents deficient for
Mrap2 are obese even in the absence
of excess food. Moreover, selective
loss of Mrap2 in neurons expressing
the transcription factor single-minded 1
(Sim1) recapitulates the obese pheno-
type observed in global Mrap2 defi-
ciency, consistent with the notion that
Sim1 neurons expressing MC4 receptors
are key regulators of energy balance
(Balthasar et al., 2005; Holder et al.,
2000). Notably, Asai and colleagues
found four rare heterozygous variantseptember 3, 2013 ª2013 Elsevier Inc. 309
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Figure 1. Role of Mrap2 in the Regulation of Central Melanocortin
Receptors in Zebrafish, Mice, and Humans
(A) In zebrafish, Mrap2a inhibits, whereas Mrap2b stimulates, the activity of
MC4 receptors (upper panel). In rodents, Mrap2 stimulates the activity of
MC4 receptors (lower panel).
(B) In humans, four rare heterozygous Mrap2 variants have been identified.
Subjects carrying the E24X variant exhibit severe obesity, subjects with the
two variants N88Y and R125C are moderately obese, and subjects with the
L115V variant display normal BMI.
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(Figure 1) (Asai et al., 2013).
The subject carrying the
E24X variant exhibited se-
vere obesity, while two of
the remaining subjects
(N88Y and R125C variants)
were modestly obese com-
pared to the subject carrying
the normal BMI variant
(L115V) (Figure 1).
In the companion report,
Sebag et al. explore the role
of Mrap2 in a zebrafishmodel
(Figure 1) (Sebag et al., 2013).
The authors demonstrated
that the paralog zMrap2a is
restricted to larval develop-
ment, whereas zMrap2b is
expressed in the adult. Using
knockdown and expression
assays, Sebag et al. show
that zMrap2a abrogates MC4
receptor signaling, thereby
stimulating larval growth,
whereas zMrap2b mimics
mammalian Mrap2 by in-
creasing the receptors’ sen-
sitivity to ligand (Figure 1).
The authors predict that thedifferential expression and regulation
of zMrap2a and zMrap2b is necessary
to properly regulate energy needs
throughout life. It is intriguing to also
think of these findings within the context
of metabolic alterations in the pre- or peri-
natal environment that may be linked
to long-lasting metabolic effects in the
offspring.
To date, very few compounds have
been successfully developed to treat
obesity. This is due, at least in part, to
the inherent difficulty in developing agents
that regulate food intake and energy
expenditure. Given their key role in regu-
lating metabolism, MC4 receptors are
compelling candidates in the search for
therapeutic targets for the treatment of
obesity (Wikberg and Mutulis, 2008).
However, evidence for melanocortin
receptor-induced changes in blood pres-
sure have raised concerns about MC4
receptors in the treatment of obesity
(Greenfield et al., 2009; Sohn et al., 2013;
Wikberg and Mutulis, 2008). Furthermore,
MC4 receptors have been implicated in
anorectic conditions including cachexia
(Marks et al., 2001). The companion re-
ports demonstrate that Mrap2 accessory310 Cell Metabolism 18, September 3, 2013 ªproteins differentially regulate the activity
of MC4 receptors by activating or inhibit-
ing MC4-dependent signaling. Thus, it
may be possible to develop novel strate-
gies for altering specific activities of MC4
receptors, which may provide avenues
for promoting the beneficial effects of
MC4 receptors on metabolism while mini-
mizing the adverse side effects.
The current studies raise many ques-
tions for future investigation. For
instance, the functional relationship
between Mrap2 and MC4 receptors is
not fully understood. Mice deficient for
Mrap2 do not display all of the metabolic
hallmarks of MC4 receptor deficiency,
suggesting that Mrap2 may regulate
other melanocortin receptors. In addition,
it remains possible that Mrap2 expres-
sion in peripheral tissues also contributes
to metabolic regulation outside the CNS.
Furthermore, Sebag et al. predict that the
Mrap proteins likely regulate the activity
of other GPCRs as well, which would
extend the complexity of the physiology
of this family of proteins. In terms of their
role in obesity, it remains to be deter-
mined whether additional Mrap2 vari-
ants are involved in the pathogenesis2013 Elsevier Inc.of the more common forms
of obesity. Finally, in order to
develop pharmacotherapy for
the treatment of various
metabolic disorders, future
work will need to clarify how
many factors are involved in
the regulation of melanocortin
receptors and their specific
molecular mechanisms.
The companion papers are
also excellent examples of
the power of combining
studies in parallel model sys-
tems (zebrafish, mice, and
humans) using multiple strate-
gies. In recent years, there has
been an exponential increase
in the use of targeted molecu-
lar strategies in various animal
models, allowing detailed ex-
amination of feeding behavior
as well as energy and glucose
homeostasis. However, some
of these studies have gener-
ated conflicting data on the
roles of receptors, enzymes,
neuropeptides, and other fac-
tors affecting metabolism.
Moreover, studies of meta-bolism in model organisms have not
always translated well into human meta-
bolic (patho)physiology. Asai et al. and
Sebag et al. nicely demonstrate that a
tractable system in model organisms
(i.e., zebrafish and rodents) may accel-
erate metabolic research and potentially
drug discovery in humans. As the field
moves forward, it will be critical to inte-
grate basic science in animal models
with human physiology to develop tools
to combat the growing epidemics of
obesity and diabetes.REFERENCES
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